Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APS001F with Flucytosine and Maltose in Advanced Solid Tumors
NCT01562626Phase 2Suspended
- Sponsor
- Anaeropharma Science
- Start
- Sep 2012
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of APS001F in solid tumor, sponsored by Anaeropharma Science. Primary endpoint: Number of participants with adverse events. Started Sep 2012; status: suspended.
02
Drugs
APS001F
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01562626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562626.